EP3407867A1 - Dermatologische oder kosmetische zusammensetzungen mit einem polyphenol-angereicherten extrakt aus vitex negundo - Google Patents

Dermatologische oder kosmetische zusammensetzungen mit einem polyphenol-angereicherten extrakt aus vitex negundo

Info

Publication number
EP3407867A1
EP3407867A1 EP17701539.3A EP17701539A EP3407867A1 EP 3407867 A1 EP3407867 A1 EP 3407867A1 EP 17701539 A EP17701539 A EP 17701539A EP 3407867 A1 EP3407867 A1 EP 3407867A1
Authority
EP
European Patent Office
Prior art keywords
extract
vitex negundo
skin
composition
polyphenols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17701539.3A
Other languages
English (en)
French (fr)
Inventor
Sophie Leclere-Bienfait
Philippe Msika
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Expanscience SA
Original Assignee
Laboratoires Expanscience SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Expanscience SA filed Critical Laboratoires Expanscience SA
Publication of EP3407867A1 publication Critical patent/EP3407867A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • the present invention relates to a cosmetic or dermatological composition
  • a cosmetic or dermatological composition comprising a Vitex Negundo extract enriched in polyphenols.
  • the composition according to the invention is advantageously useful in the prevention or treatment of disorders or pathologies of the skin, mucous membranes or integuments, and in the prevention or treatment of vascular disorders.
  • Vitex Negundo has the common name Blue Lily or Chinese Troon, and is called Nôti in Reunion, Chinduravam Notchi in Tamil, or Huang Ping in Chinese for example.
  • Vitex Negundo is a shrub native to India belonging to the Verbenaceae or Lamiaceae family, up to one to two meters tall, with small blue to violet flowers of three to five millimeters. The leaves, which are the most used in traditional medicine, break down into three or five leaflets of lanceolate form. This plant is widely distributed throughout the world and is found in Afghanistan, Pakistan, Sri Lanka, East Africa, Madagascar and is widely grown in Asia, Europe, North America. The phytochemistry of Vitex Negundo has been described by Vishal R. Tandon (Natural Product Radiance 2005, 4 (3), 162-165) and Vishwanathan et al (EJBS 2010, 3 (1), 30-42), and is summarized in the table below.
  • Delta-guaiene essential oil guaiai-3, 7-dienecaryophyllene epoxide, fresh ethyls, flowers and hexadecenoate, alpha-selinene, germacrene-4-ol, caryophyllene dry fruits epoxide, nerilidol, betaselinene, alpha-cedrene, germacrene D, hexadecanoic acid, p-cymene, valencene
  • Extracts of various parts of the plant Vitex negundo grown or obtained in its natural environment have multiple pharmacological properties. The following have been identified:
  • analgesic and analgesic properties in particular leaf and root extract administered in the peritoneum;
  • anti-inflammatory properties and especially anti-arthritic and anti-arthritic properties, leaves, roots and seeds;
  • Vitex Negundo is used in Réunion for the treatment of chikungunya seizures (S. SAVRIAMA - Ethnopharmacologia, No. 52, 2014).
  • Vitex Negundo is often used in decoction, mainly leaves, and more rarely roots.
  • Vitex Negundo In Ayurvedic rites, the plant Vitex Negundo is used for its deworming and antihelminthic properties.
  • the "traditional" extracts of Vitex Negundo exhibit a phytochemical composition, that is to say a concentration of active principles, and especially polyphenols, which is not optimal for cosmetic or dermatological applications.
  • extracts of Vitex Negundo with a high content of flavonoids have been described in CN 104586700 (flavone content greater than or equal to 82.5%), and by Huang et al (Journal of Pharmaceutical and Biomedical Analysis, 2015, 108, 11 -20).
  • the extracts of the invention have in fact a content of at least 5% by weight of polyphenols, expressed in gallic acid equivalent, relative to the total weight of the dry extract, higher than extracts of Vitex Negundo obtained from cultivated plants. in earth. Nevertheless, the extracts of the invention have a low or no content in flavonoids.
  • Vitex negundo grown in these particular aeroponic conditions, with in particular a suitable nutrient solution and a suitable elicitor, does not produce the molecules usually described in the prior art for this plant, in particular flavonoids. Extremely described that are the vitexin and its derivatives, unlike the mother-plants cultivated under usual conditions in earth.
  • Vitex Negundo extracts enriched in polyphenols have anti-inflammatory, antioxidant and anti-pollution properties.
  • inflammatory phenomena, radical attacks, phenomena amplified by pollution and UV exposures are at the origin of chronological and actinic aging phenomena. Extracts of Vitex Negundo enriched polyphenols and cosmetic and dermatological compositions comprising them are therefore useful for example as anti-aging care, especially against chronological and actinic aging of the skin, mucous membranes or integuments.
  • the present invention thus relates to a cosmetic or dermatological composition
  • a cosmetic or dermatological composition comprising an extract of Vitex Negundo enriched in polyphenols as active ingredient, and optionally a suitable excipient.
  • the present invention also relates to a cosmetic or dermatological composition
  • a cosmetic or dermatological composition comprising an extract of Vitex Negundo enriched in polyphenols, for use in the prevention or treatment of disorders or pathologies of the skin, mucous membranes or integuments, and in the prevention or control of treatment of vascular disorders.
  • the present invention also relates to a method for the cosmetic care of the skin, superficial body growths or mucous membranes, with a view to improving their state or appearance, comprising or consisting in the administration of a composition of the invention.
  • Vitex Negundo extract rich in polyphenols or "Vitex Negundo extract enriched in polyphenols” means an extract of Vitex Negundo comprising at least 5% by weight, for example between 5% and 10% by weight. of polyphenols, expressed in gallic acid equivalent, relative to the total weight of the dry extract. These percentages are in particular obtained by a Folin-Ciocalteu assay.
  • a Folin-Ciocalteu assay all the phenolic compounds are oxidized by the Folin-Ciocalteu reagent (commercially available).
  • the latter comprises a mixture of phosphotungstic acid (H3PW12O40) and phosphomolybdic acid (H3PM012O40) which is reduced, during the oxidation of the phenolic substances, to a mixture of blue oxides of tungsten (W 8 0 2 3) and of molybdenum (Mo 8 0 23 ).
  • the blue color produced has a maximum absorption around 750-760 nm. It is proportional to the amount of oxidized phenolic compounds.
  • the reference phenol used in this method is gallic acid. The results obtained by this assay are therefore expressed in "% by weight of polyphenols, expressed in gallic acid equivalent, relative to the total weight of the dry extract".
  • Flavonoids are a subclass of polyphenols, having an optionally substituted carbene backbone, said 15-carbon backbone comprising a first bicycle composed of a phenyl ring fused to a 6-membered (oxygenated) heterocycle substituted with a phenyl ring. .
  • the content of flavonoids is expressed in% by weight relative to the total weight of the dry extract, and is measured by methods well known to those skilled in the art, such as the chromatographic methods described in particular by Mai (J. Sci.
  • “Vitex Negundo extract rich in polyphenols” or “Vitex Negundo extract enriched in polyphenols” is enriched in dicafeoylquinic acid derivatives (DCQ), especially 3,5-Di-Caffoyl-Quinic acids ( 3,5-DCQ) and 4,5-Di-Caffoyl-Quinic (4,5-DCQ).
  • DCQ dicafeoylquinic acid derivatives
  • 3,5-DCQ 3,5-Di-Caffoyl-Quinic acids
  • 4,5-DCQ 4,5-Di-Caffoyl-Quinic
  • Dicaffeoylquinic acid (which can be abbreviated as “DCQ” in the present description) is meant a diester composed of a quinic acid molecule of which two of the four alcohol functions have been esterified with caffeic acid. Dicaffeoylquinic acids are therefore acids of general formula (I):
  • any two of the radicals R 2 , R 3, R 4 and R 5 represent a caffeine group, the other two representing a hydrogen atom.
  • caffeyl group is meant a radical of general formula (II), derived from caffeic acid:
  • the different isomers of DCQ are thus acids of general formula (I), with R 2 , R 3, R 4 and R 5 as defined in the table below.
  • the term "part” of a plant any constituent part of a plant such as roots, stem, leaves, fruit, skin, seeds or the nucleus.
  • Root exudation means the recovery of metabolites contained in the roots of plants by means of a liquid brought into contact by percolation, spraying or immersion with the roots, still attached to the living plant or freshly cut (for less than 24 hours, and preferably as soon as possible after cutting, ideally just after cutting).
  • the root exudation can be carried out by means of a step of maceration of the plants roots, freshly cut and / or attached to the living plant, in a suitable solvent and for a suitable duration.
  • the term "cosmetically acceptable” is understood to mean that which is useful in the preparation of a cosmetic composition which is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for a cosmetic use, in particular human use. .
  • the term "dermatologically acceptable” is intended to mean that which is useful in the preparation of a dermatological composition which is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for dermatological use, in particular human use. . detailed description
  • the present invention relates in the first place to a cosmetic or dermatological composition
  • a cosmetic or dermatological composition comprising a Vitex Negundo extract rich in polyphenols as active principle, and where appropriate a suitable excipient, in particular dermatologically or cosmetically acceptable.
  • the Vitex Negundo extract rich in polyphenols of the compositions of the invention is preferably in liquid form.
  • the contents of the various constituents (in particular the polyphenols, and more particularly the DCQ) of the extract are expressed relative to the weight of the "dry” extract.
  • This "dry” extract is typically obtained by evaporation of the solvent in an oven at 105 ° C, until a constant weight extract is obtained.
  • the "dry” extract thus obtained is therefore essentially devoid of volatile substances, in particular solvents and in particular water.
  • the Vitex Negundo extract enriched in polyphenols is advantageously obtained by a process involving the planting plant technology ® Plant Advanced Technologies (technology described in particular in the international application WO 01/33942) which allows for successive extractions to from the roots of the plant (milking) without destroying it.
  • the plants are cultivated aeroponie and are fed by root spraying a solution of essential nutrients (Nitrogen - N, Phosphorus - P, Potassium - K), precisely developed in terms of proportions and concentration. , in order to obtain a maximum root development, without altering the survival of the plant.
  • the plant is punctually stressed and / or elicited by appropriate substances, allowing a better production of the molecules identified as of interest, here polyphenols, including DCQ, including 4,5-DCQ.
  • Vitex Negundo extracts rich in polyphenols of the compositions of the invention are obtained according to a process comprising the following successive stages:
  • the skilled person with the help of his general knowledge, knows how to adapt the proportions and concentrations of different mineral salts to optimize the root development and concentration of the molecules of interest.
  • the mineral salt concentrations of the nutrient solutions are advantageously in a range of electroconductivity ranging from 0.2 to 1.6 mS.
  • Step a) is advantageously carried out for a period of between 1 week and eight weeks.
  • the stimulation step b) makes it possible to significantly increase the content of the metabolites in the roots and thus promote the flow comprising the metabolites leaving the roots to the chosen solvent for the maceration and without any loss of the viability of the plant so that it can be reused.
  • the stimulation step of the plant makes it possible to promote the content and the secretion of the molecules of interest.
  • the stimulation step b) is carried out by spraying the plant with a solution of elicitors chosen from jasmonic acid derivatives, ethylene generators, chitin, chitosan and their mixtures.
  • step b) is advantageously carried out for a period of between 1 day and two weeks.
  • Step b) can be performed simultaneously or after step a).
  • the stimulation solution can be introduced into the nutrient solution.
  • step c) extraction by root exudation under conditions determined in terms of extraction solvent, pH and extraction time, in order to obtain an extract rich in molecules of interest, that is to say polyphenols, especially dicaféoylquiniques acids.
  • This step c) allows the recovery of metabolites (DCQ) released by plant roots by means of a liquid contacted by percolation or immersion with the roots.
  • the root excretion step c) is carried out by maceration of the roots for a period of between 30 minutes to 96 hours, in particular between 12 hours and 72 hours, more particularly between 24 hours and 48 hours.
  • the duration of root exudation is chosen so as to favor the extraction of a high content of compounds of interest while not altering the survival of the plant and without leading to the depletion of resources.
  • the extraction is advantageously carried out at acidic pH.
  • the isomerization step d) is carried out according to techniques known to those skilled in the art, in particular by successive readjustment of the pH of the extract (extraction at acidic pH, readjustment at basic pH with a strong base solution and final readjustment). at acidic pH by the addition of a strong acid).
  • Stage d) makes it possible to obtain an extract of Vitex Negundo, characterized in that the majority of the dicafeoylquinic acids which it comprises are in the form of the 4,5-butadioquinyl isomer.
  • the extract obtained after step d) is subjected to a final step e) of purification and concentration by successive filtrations, in particular by nanofiltration and / or sterilizing filtration. This stage makes it possible to obtain the final extract of Vitex Negundo rich in polyphenols, in particular in DCQ.
  • the extract thus obtained may be in liquid or solid form.
  • the extract in solid form is advantageously obtained by drying the liquid extract, according to the methods known to those skilled in the art, such as atomization or lyophilization for example with or without a carrier such as maltodextrin.
  • the Vitex Negundo extract rich in polyphenols of the compositions of the invention advantageously comprise at least 5%, for example between 5% and 10%, in particular at least 6%, more particularly at least 7%, by weight of polyphenols, expressed in gallic acid equivalent, relative to the total weight of the dry extract.
  • the Vitex Negundo extract rich in polyphenols of the present invention advantageously comprises at least 7% by weight of polyphenols, the percentages being expressed relative to the total weight of the dry extract of said extract (before any addition of a drying medium) or 1.3 mg of polyphenols per mL of liquid extract and more specifically at least 5% by weight of total DCQ, ie 1.1 mg of DCQ per mL of liquid extract.
  • DCQs are particularly interesting.
  • the extract according to the invention can be characterized by its content of DCQ, and more particularly a mixture of its different isomers, mainly comprising 4, 5 -DCQ.
  • the Vitex Negundo extract enriched in polyphenols thus advantageously comprises at least 1.5%, in particular at least 2.5%, more particularly at least 4%, in particular at least 5%, preferably at least 6%, by weight of the dicaffeoylquinic acids, relative to the total weight of the dry extract.
  • Said dicaffeoylquinic acids are in particular the isomers of 3,4-dicaféoylquinique acid (3,4-DCQ), 3,5-dicaféoylquinique (3,5-DCQ) and 4,5-dicaféoylquinique (4,5-DCQ).
  • At least 40% by weight of the dicaféoylquiniques acids are in the form of the 4,5-dicaféoylquinique isomer, relative to the total weight of dicaféoylquiniques acids.
  • the Vitex Negundo extract enriched in polyphenols obtained by the above process has the particularity of containing a very small amount of flavonoids, usually present in large quantities in the Vitex Negundo extracts of the prior art.
  • the plant Vitex Negundo grown under the conditions outlined above synthesizes and secretes a very small amount of flavonoids such as vitexin and its derivatives.
  • the Vitex Negundo extract enriched in polyphenols comprises less than 0.5% by weight, preferably less than 0.2%, in particular less than 0.1%, more particularly less than 0.05%, in particular less than 0.01%, by weight of flavonoids, relative to the total weight of the dry extract.
  • the cosmetic or dermatological composition contains 0.001 to 10%, typically 0.01 to 5%, by weight of Vitex Negundo extract rich in polyphenols relative to the total weight of the composition.
  • the Vitex Negundo extract rich in polyphenols is preferably in liquid form.
  • composition and / or the active compounds according to the invention may further comprise at least one dermatologically acceptable excipient, or a cosmetically acceptable excipient.
  • an excipient suitable for external topical administration is used, in particular on the skin, superficial body growths and / or mucous membranes, in particular skin, dander and / or mucous membranes that are sensitive or attacked by the environment. for example by UV or pollution.
  • composition will advantageously be in the form of a preparation adapted for topical administration, in particular including creams, emulsions, milks, ointments, lotions, oils, aqueous or hydro-alcoholic or glycolic solutions, powders, patches, sprays, shampoos, varnishes or any other product for external application.
  • composition according to the present invention may further comprise at least one dermatological or cosmetic adjuvant known to those skilled in the art, chosen for example from thickeners, preservatives, perfumes, dyes, chemical or mineral filters, moisturizing agents. , thermal waters, etc.
  • dermatological or cosmetic adjuvant known to those skilled in the art, chosen for example from thickeners, preservatives, perfumes, dyes, chemical or mineral filters, moisturizing agents. , thermal waters, etc.
  • composition may further comprise at least one other active compound in addition to Vitex Negundo extract rich in polyphenols.
  • the invention also relates to a composition according to the invention for use in preventing and / or treating:
  • composition according to the invention is intended for the prevention and / or treatment of inflammatory reactions, oxidation reactions, disorders related to radical attacks related or not to pollution, barrier disorders or homeostasis of immature, normal, or mature / aged skin, integument (hair and nails) and / or mucous membranes (gingiva, periodontal, genital mucosa).
  • compositions of the invention are useful as an anti-aging care, especially against the chronological and actinic aging of the skin, mucous membranes or superficial body growths.
  • composition according to the invention can be used for the prevention and / or treatment of reactions, disorders or pathologies:
  • skin especially rosacea or erythrocouperosis, sensitive skin, reactive skin, dry skin (xerosis), dehydrated skin, skin with redness, erythema, aged or photoaged skin, photosensitized skin, pigmented skin (melasma, post-inflammatory pigmentation ...), loose skin;
  • - mucous membranes such as gums and periodontitis that may present with gingivitis (sensitive gums of newborns, hygiene problems, due to smoking or other), periodontal disease, or genital mucosa that may present irritations of the male or female genital spheres external or internal, and / or
  • the composition according to the invention is also particularly useful in the prevention and / or treatment of vascular disorders, in particular for the protection of the blood vessels and / or to act on the blood circulation, in particular the blood microcirculation.
  • the vascular disorder is typically selected from: rosacea, skin rashes, rosacea, pruritus, skin and / or reactive mucosa, with redness, particularly due to dilation of the subcutaneous capillaries.
  • the composition according to the invention is useful in the prevention and / or treatment of redness and rosacea, as well as in the prevention and / or treatment of cutaneous aging linked to intrinsic or extrinsic causes.
  • composition according to the invention is therefore advantageously used in the prevention and / or treatment of the (chronic) dilation of the subcutaneous capillaries which can occur in conditions such as rosacea, skin rashes, rosacea, pruritus, skin and / or reactive mucosa, with redness, especially due to dilation of the subcutaneous capillaries.
  • composition according to the invention is also advantageously used as a chronological or photoinduced anti-aging product, in particular in the prevention of aging, and photoinduced aging.
  • composition according to the invention is also advantageously used as a healing product, in the prevention and / or treatment of disorders related to cicatrization and cutaneous organization.
  • disorders related to cicatrization and cutaneous organization disorders resulting from healing processes and cutaneous organization of the skin such as loose skin, stretch marks, scabs, cracks, crevices in particular at the level of the breasts.
  • composition according to the invention is used (e) as a moisturizing product, involved in the prevention and / or treatment of disorders of the barrier or homeostasis of the skin, superficial body growths (hair and nails) and / or mucous membranes (gingiva, periodontitis, genital mucosa) immature, normal or mature / aged.
  • disturbances of the skin barrier superficial body growths and / or mucous membranes are meant disorders occurring at the level of the outer layer of the epidermis.
  • homeostasis disorders of the skin, superficial body growths and / or mucous membranes is understood to mean the disorders resulting from cell renewal and equilibrium processes such as psoriasis, dermatitis of the seat, atopic dermatitis, dry skin ( xerosis), dehydrated skin and photosensitized skin.
  • composition according to the invention is also advantageously used in the treatment and / or prevention of inflammations due to rays of all kinds, in particular sunburn.
  • composition according to the invention is also advantageously used as a depigmenting or brightening product, especially in the treatment of pigmented skin (melasma, post-inflammatory pigmentation, etc.), or for reducing age spots, for example.
  • the invention also relates to a method for the cosmetic care of the skin and / or integuments and / or mucous membranes, with a view to improving their state and / or their appearance, comprising or consisting of the administration, preferably topically, of a composition according to the present invention.
  • the invention relates to a method for the cosmetic care of the skin, with a view to preventing aging, comprising or consisting of applying to the skin a composition according to the present invention.
  • the composition of the invention is used as a chronological or photoinduced anti-aging product, or as a moisturizing product.
  • the composition of the invention is used as a depigmenting or lightening product, especially in the treatment of pigmented skin (melasma, post-inflammatory pigmentation ...), or to reduce old age tasks for example.
  • the modes of administration, the dosages and the optimal dosage forms of the compounds and compositions according to the invention can be determined according to the criteria generally taken into account in the establishment of a dermatological and / or cosmetic treatment adapted to a patient, such as for example the age or body weight of the patient, the severity of his general condition, the tolerance to treatment, the side effects noted, the type of skin.
  • a polyphenolic extract of Vitex negundo enriched in polyphenols, in particular in DCQ, is obtained according to the following process:
  • the extract is purified (removal of salts by nanofiltration) and concentrated by successive filtrations including nanofiltration and sterilizing filtration.
  • the Vitex negundo extract enriched in liquid polyphenols thus obtained has the following characteristics (% on dry extract, obtained by evaporation of the solvent in a ventilated oven at 105 ° C. until an extract with a constant weight):
  • non PAT extract An extract of dry roots and dry leaves from a plant of Vitex negundo grown in soil according to conventional techniques (called “non PAT extract”), but in the same environment (greenhouse), is obtained according to the following modalities:
  • the assay values obtained by HPLC are as follows (%, concentration of the molecules of interest / dry extract of the total extract obtained):
  • the PAT extract does not contain flavonoids. But specifically, it contains a much higher concentration of polyphenols, including hydroxycinnamic derivatives. II. Biological Activities
  • a Vitex Negundo liquid extract of the invention obtained according to the process of Example 1 (process comprising step d) of isomerization ) is used. This one is possibly tested for different dilutions.
  • the Vitex Negundo extracts of the invention are then characterized by their concentration relative to the concentration of the initial extract, the concentration being expressed in% of corresponding dry extract introduced.
  • Vitex negundo extract enriched in polyphenols were investigated by a gene expression modulation test on melanized reconstructed dermal and epidermal fibroblasts.
  • the expression of 95 genes of major interest in cutaneous and cosmetic physiology was studied by PC-array on melanized reconstructed fibroblasts and epidermis.
  • the extract of Vitex negundo enriched in polyphenols (0.01%, dry matter) was added to the culture medium of fibroblasts or melanized human epidermis reconstituted for 6h and 24h.
  • the expression of the selected markers was evaluated by quantitative RT-PCR (microfluidic map).
  • the expression variation of the markers studied with respect to the control was expressed in relative expression (RQ, RQ> 1: increase, RQ ⁇ 1: decrease).
  • Urokinase plasminogen activator type plays a role in the migration of keratinocytes during the process of re-epithelialization during cutaneous cicatrization;
  • DPT Dermatopontine
  • CYR61 Protein plays a role in the remodeling of the dermal matrix by reducing the production of dermal matrix component, activating metalloproteinases and activating the expression of pro-inflammatory cytokines.
  • Anti-microbial, anti-oxidant and anti-inflammatory defenses are important because of:
  • HMOX1 Heme oxygenase 1
  • Lactotransferrin exhibits anti-microbial activity by its ability to bind to iron, stimulates re-epithelialization, proliferation of keratinocytes and fibroblasts and activates the synthesis of extracellular matrix components;
  • Prostaglandin G / H synthase 2 (PTGS2): an enzyme that catalyzes the synthesis of prostaglandin, a marker involved in the activation of inflammation.
  • the dermal-epidermal junction The dermal-epidermal junction:
  • Collagen 7 alpha 1 (COL7A1): component of the dermal-epidermal junction, form of fibrils allowing the attachment of the basal lamina to the dermis.
  • LAMB3 Laminin subunit (“subunit”) beta-3 (LAMB3): constituent of the basal lamina which allows the attachment of the basal lamina to the epidermis.
  • Kallikrein 5 (KLK5): involved in the maturation of the stratum corneum.
  • Vitex negundo extract enriched in polyphenols In order to study the potential of Vitex negundo extract enriched in polyphenols on the dermal matrix and its aging, its effect on the level of gene expression of extracellular matrix markers (ECM) was evaluated. The study was performed on normal dermal fibroblasts. The effect of Vitex negundo extract enriched in polyphenols was also evaluated on fibroblasts as a function of age using cells from a 28-year-old donor, a 54-year-old donor, and fibroblasts. from the 28-year-old donor, made senescent in vitro by successive replications.
  • ECM extracellular matrix markers
  • Normal human fibroblasts were treated for 24 h and 48 h with Vitex negundo extract enriched in 0.005% and 0.01% polyphenols.
  • a control was performed by treating fibroblasts with monopropylene glycol (extraction solvent).
  • the gene expression of the selected markers was analyzed by quantitative T-PC in real time.
  • the level of gene expression was expressed as a relative amount (RQ) and the effect of treatment versus control cells as a percentage increase.
  • Vitex Negundo extract enriched in polyphenols significantly increased the gene expression of elastin, fibrillin, decorin and collagen VII. All these proteins are structural proteins of the dermal matrix. Elastin and fibrillin are markers involved in the elasticity of the dermis. Decorin controls the proper assembly of the collagen network. Collagen VII is a marker present in the dermal-epidermal junction and allows good anchoring of the matrix to the epidermis. By increasing these markers, the extract of Vitex Negundo enriched with polyphenols thus seems to contribute to the maintenance of a good structure of the dermis.
  • Vitex Negundo extract enriched with polyphenols significantly increased the gene expression of collagen III, decorin, dermatopontin, collagen IV and significantly decreased the MMP1 marker. All these proteins participate in the development of the dermal matrix.
  • decorin controls the proper assembly of the collagen network and collagen IV as collagen VII is a marker present in the dermal-epidermal junction which allows the proper anchoring of the matrix to the epidermis.
  • the MMPl as for it, is an enzyme that catalyzes the breakdown of collagens. By inhibiting MMP1 and increasing the other markers, the Vitex Negundo extract enriched in polyphenols thus seems to promote the synthesis and good structure of the dermal matrix.
  • the fibroblasts were aged in vitro by successive replications.
  • the senescence was verified by the evaluation of senescence markers (increase of the beta-galactosidase marker, increase of the p21 gene marker (+ 145%)).
  • the results presented below correspond to a treatment duration of 24 hours.
  • Extract of Vitex Negundo enriched with polyphenols increased the gene expression of decorin, collagen VII and sirtuin 1.
  • the first two markers are involved in the structure of the dermal matrix and its good attachment to the basal lamina.
  • Sirtuin 1 is a marker of longevity that delays cellular senescence. By increasing these markers, Vitex Negundo extract enriched in polyphenols thus seems to contribute to maintain a good structure of the dermal matrix and to slow cell senescence.
  • Vitex Negundo extract enriched in polyphenols on the dermal matrix has been demonstrated on "young", “aged” and “senescent” fibroblasts. Extract Vitex Negundo seems to contribute to the maintenance of a good structure of the dermal matrix and thus help protect the skin from skin aging.
  • the cells are then treated in the presence of 0.5 mM DCFH-DA.
  • Oxidation is induced by adding H 2 0 2 at ⁇ for 20min.
  • a second treatment with the tested products is carried out simultaneously with H 2 O 2 stress (at the same concentrations as the pre-treatment).
  • DFU fluorescence density
  • ROS reactive oxygen species
  • ROS reactive oxygen species
  • Vitamin C 500 ⁇ 11940 872 -91 * * * * * * * * * * * * * * * * * * * * * * * * * *
  • the extract of Vitex Negundo enriched in polyphenols has demonstrated a strong antioxidant effect against a stress induced by H 2 0 2 .
  • the inflammatory response is the normal, immediate and transient response of the body to any aggression of the environment. However, under certain pathological or physiological conditions, this inflammatory reaction can be exacerbated and, poorly controlled, can lead to tissue damage.
  • the keratinocyte is one of the first cells involved in the initiation of the inflammatory reaction in response to an attack on the environment.
  • ILla Primary cytokines
  • IL8 secondary cytokines
  • PGE Prostaglandins
  • Vitex Negundo extract enriched in polyphenols was evaluated on a model of inflammation induced on keratinocytes by treatment with PMA (Phorbol 12-Myristate 13-Acetate).
  • PMA Phorbol 12-Myristate 13-Acetate
  • the release of Interleukin-1 beta ( ⁇ ) and Prostaglandin E2 (PGE2) cytokines was analyzed.
  • Inflammation was then induced by adding PMA at 10 ⁇ g / mL overnight.
  • the number of biologically active cells was determined by a Neutral Red test.
  • the amount of cytokine assayed for each condition was normalized to the number of living cells determined by the neutral red test.
  • the Vitex Negundo extract enriched in polyphenols pretreated 24h at both concentrations, significantly decreased the release of ⁇ and therefore showed an anti-inflammatory action against the PMA.
  • Vitex Negundo extract enriched in polyphenols pretreated 24h at both concentrations, significantly decreased the release of PGE2 and therefore showed an anti-inflammatory action against the PMA.
  • Vitex Negundo extract enriched in polyphenols was demonstrated by its action on the release of interleukin-1 beta and prostaglandin E2 in inflammatory conditions. 11.4. Anti-aging effect on skin explant
  • Vitex Negundo extract liquid was used in a cream composition comprising 0.08% or 2% by weight of said extract relative to the total weight of the cream.
  • Quantitation of the fluorescence was performed using the Image J software. On average, ten images per explant were taken.
  • Elastin is a key component of the extracellular dermal matrix. This protein contributes to a large extent to the elasticity of the dermis. Collagen VII, for its part, is a marker of the dermal-epidermal junction. The latter serves to anchor the dermis to the epidermis and thus allows the maintenance of the general structure of the skin.
  • Klotho protein is a protein involved in the aging process and would be related to longevity. Its increase would go in favor of an induction of longevity and thus delay skin aging.
  • Vitex Negundo extract enriched with polyphenols has thus demonstrated an anti-aging effect on the explant model.
  • Normal human fibroblasts were treated for 48h with Vitex Negundo extract at 0.001% and 0.01% (w / v).
  • an extraction solvent control was performed by treating fibroblasts with monopropylene glycol (control cells). The study was performed on normal human fibroblasts. After 48 hours of treatment, the cells are trypsinized and frozen.
  • nuclear extracts are prepared and a protein assay is performed.
  • the extracts are then deposited on a chip functionalized with plasmids comprising series of specific DNA lesions:
  • the DNA repair enzymes contained in the extracts excise the lesions (or the DNA fragment surrounding the lesions) and incorporate a marker (dNTP-biotin) at the same time. DNA resynthesis.
  • the incorporated biotin is revealed by Streptavidin coupled to a fluorochrome, Cy-5.
  • the fluorescent signal is quantified using a scanner. It is proportional to the Excision / Resynthesis capacities of each extract vis-à-vis each of the lesions. This test is used to characterize Basic Excision Repair (BER), Nucleotide Excision Repair (NER), and Inter-Strand Adduct Repair (ICLR) systems.
  • Vitex Negundo extract enriched with polyphenols promotes DNA repair pathways of 8-oxo-2'-deoxyguanosine (p8oxoG), abasic sites (pAbas), benzo [a] pyrene adducts (pBPDE) and alkylated bases (pEtheno). It seems to help reduce the premature aging of the skin caused by unrepaired DNA damage.
  • the epidermis consists of numerous free nerve endings from sensory neurons from the spinal ganglia along the spinal cord. These neurons have axons that transmit information such as touch, heat, pain for example.
  • the density of innervation varies during aging. Thus, the innervation of a given area is less important in an elderly person than in a young adult. This phenomenon leads to a decrease in the individual's ability to apprehend his environment.
  • One of the properties of sensory neurons is their ability to re-innervate areas of the skin that have partially lost this density of free endings. Keratinocytes release growth factors allowing neurons to emit free endings to the outermost layers of the epidermis. The aim of this study was to evaluate the potential of the Vitex Negundo extract on the tropism of sensory neurons and on their ability to emit prolongations in the presence of aged keratinocytes.
  • Sensory neurons are derived from hiPS cells obtained from human fibroblasts.
  • the hiPS were seeded in co-culture with keratinocytes from a 33-year-old donor and a 59-year-old donor.
  • Co-cultures were treated with Vitex Negundo extract at different concentrations (0.003% / 0.001% / 0.0005% / 0.0001% / 0.00005% / 0.00001%, (w / v)) by 0.1% monopropylene glycol (extraction solvent control) and 50ng / mL Nerve Growth Factor (NGF) as a positive reference for dendrite elongation.
  • NGF Nerve Growth Factor
  • the cells were fixed with a 2% paraformaldehyde solution and then labeled with an anti-tubulin antibody.
  • the labeling was observed using a fluorescence microscope and 20 images were acquired by co-culture.
  • the length of sensory neuron prolongations was measured and normalized by the number of labeled cell bodies. All the statistics were made using the t-test and the ANOVA test (* p ⁇ 0.05; ** p ⁇ 0.01; *** p ⁇ 0.001).
  • NGF at 50 ng / mL significantly increased total neurite length as well as neurite length per cell. This result validates the model.
  • Vitex Negundo extract enriched in polyphenols significantly induced the increase in the total length of the neurites as well as the length of the neurites per cell in co-cultures of human sensory neurons / aged keratinocytes.
  • the extract of Vitex Negundo enriched in polyphenols thus seems to help prevent the decline of the network of sensory neurons in the skin observed during skin aging and thus seems to protect the skin from a loss of sensation appearing with age.
  • compositions of the invention comprising an extract of Vitex Negundo was evaluated against placebo during a clinical test.
  • the placebo is a cream containing no cosmetic active ingredients (only cosmetic excipients), and the composition according to the invention is a cream of the same composition as the placebo, further comprising 1% by weight of extract. of Vitex Negundo of the invention.
  • the test is performed on a panel of 2 groups of 25 subjects: Caucasian women of phototypes I to I, healthy, aged between 40 and 60 years old. Inclusion was decided according to different clinical scales.
  • J0 is the starting point of the study (before the application of the cream comprising the composition of the invention or placebo).
  • Group I applied the composition of the invention to the face and hands, while Group I applied a placebo to the face and hands. Both groups I and I I respectively applied the composition of the invention or placebo 2 times daily for 56 days.
  • the effect of the composition of the invention was evaluated by colorimetric measurements on the forehead, the cheek and a spot on the hands. The measured parameters are the brightness L * (expressed in arbitrary unit u.a.) and the angle ITA.
  • the measurements were carried out with a spectro-colorimeter (Minolta) which has a 3 mm head.
  • the L * parameter of the L * a * b * space gives information on the brightness of the measured skin color.
  • L * corresponds to clarity or brightness
  • a * represents the hue and saturation of the color on a green-red axis
  • b * represents the hue and saturation of the color on a blue-yellow axis.
  • the angle ITA gives information on the complexion of the skin. A high angle translates to lighter skin.
  • Measuring area skin discoloration is measured on the cheek, forehead or hand on a previously defined area identified by a tracking mask.
  • the cream to be tested the cream comprising the composition of the invention or the placebo is applied to the whole hand or face as a usual cream.
  • the asset makes it possible to increase the brightness and to lighten the skin significantly more important compared to the placebo at the level of a spot: AL * (composition): + 6%
  • the active allows to increase the brightness and lighten the skin significantly more important compared to the placebo at the forehead:
  • the asset makes it possible to increase the brightness and to lighten the skin significantly more important compared to the placebo at the level of the cheek:
  • compositions of the invention have a significant depigmenting and brightening effect compared to a placebo both at the level of a stain on the hand, on the forehead or on the cheeks.
  • Example 1 The PAT extract of Vitex negundo (VN) of Example 1 can be incorporated into various cosmetic products, such as cleaning waters, oil-in-water emulsions, water-in-oil emulsions, oils, milks, lotions. , shampoos, foaming products and sprays, the compositions of which are given below by way of examples.
  • various cosmetic products such as cleaning waters, oil-in-water emulsions, water-in-oil emulsions, oils, milks, lotions. , shampoos, foaming products and sprays, the compositions of which are given below by way of examples.
  • BIOTINE From 0 to 5% j
  • VITAMIN B9 0 to 5% j

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medical Informatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP17701539.3A 2016-01-29 2017-01-27 Dermatologische oder kosmetische zusammensetzungen mit einem polyphenol-angereicherten extrakt aus vitex negundo Withdrawn EP3407867A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1650752A FR3047175A1 (fr) 2016-01-29 2016-01-29 Compositions cosmetiques, dermatologiques comprenant un extrait de vitex negundo enrichi en polyphenols
FR1652896A FR3047177B1 (fr) 2016-01-29 2016-04-01 Compositions cosmetiques, dermatologiques comprenant un extrait de vitex negundo enrichi en polyphenols
PCT/EP2017/051826 WO2017129779A1 (fr) 2016-01-29 2017-01-27 Compositions cosmetiques, dermatologiques comprenant un extrait de vitex negundo enrichi en polyphenols

Publications (1)

Publication Number Publication Date
EP3407867A1 true EP3407867A1 (de) 2018-12-05

Family

ID=56087391

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17701539.3A Withdrawn EP3407867A1 (de) 2016-01-29 2017-01-27 Dermatologische oder kosmetische zusammensetzungen mit einem polyphenol-angereicherten extrakt aus vitex negundo

Country Status (6)

Country Link
US (1) US20190008757A1 (de)
EP (1) EP3407867A1 (de)
JP (1) JP2019508394A (de)
CN (1) CN108650881A (de)
FR (2) FR3047175A1 (de)
WO (1) WO2017129779A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3072025B1 (fr) 2017-10-06 2019-11-01 Plant Advanced Technologies Pat Extraits racinaires de plantes du genre morus et leurs utilisations
FR3080033B1 (fr) * 2018-04-12 2020-07-17 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Nouvelle composition a base d'acides polycafeoylquiniques, son utilisation en cosmetique et compositions cosmetiques en comprenant
FR3080032B1 (fr) * 2018-04-13 2020-04-17 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Utilisation d'une nouvelle composition pour empecher ou ralentir l'apparition de signes d'inflammation
FR3080030B1 (fr) * 2018-04-13 2020-04-24 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Utilisation d’une nouvelle composition pour empecher ou ralentir l’apparition des signes inesthetiques lies a la presence de sebum en exces
FR3091161B1 (fr) * 2018-12-28 2020-12-11 Expanscience Lab Extrait de chlamydomonas acidophila, son procede de preparation et les compositions cosmetiques, et dermatologiques le comprenant
US11364255B2 (en) * 2020-07-01 2022-06-21 Karallief, Inc. Therapeutic herbal compositions for improving joint health
CN114394931B (zh) * 2022-01-30 2023-07-11 西安交通大学 具有血管舒张活性的单萜生物碱及其提取方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2938253B2 (ja) * 1991-11-22 1999-08-23 ポーラ化成工業株式会社 発毛・育毛料
FR2800740B1 (fr) * 1999-11-08 2002-10-11 Lorraine Inst Nat Polytech Procede de production de metabolites a partir de vegetaux en culture hors sol
FR2837385B1 (fr) * 2002-03-20 2004-05-28 Rachid Ennamany Procede d'obtention de phytoalexines
AU2003249114A1 (en) * 2003-03-20 2004-10-11 Shiseido International France Cosmetic composition
FR2926955B1 (fr) * 2008-02-01 2012-07-20 Agronomique Inst Nat Rech Procede de preparation d'acides dicafeoylquiniques et leur utilisation dans la lutte contre les pucerons
KR20140117794A (ko) * 2013-03-27 2014-10-08 서울과학기술대학교 산학협력단 목형 잎 추출물을 함유하는 피부 외용제 조성물
CN104586700B (zh) * 2015-01-30 2017-08-29 广州赛莱拉干细胞科技股份有限公司 一种黄荆叶提取物及其制备方法与应用
CN104739730A (zh) * 2015-04-21 2015-07-01 吉首大学 一种除菌、止痒、驱蚊花露水的制作方法

Also Published As

Publication number Publication date
WO2017129779A1 (fr) 2017-08-03
FR3047177A1 (fr) 2017-08-04
US20190008757A1 (en) 2019-01-10
JP2019508394A (ja) 2019-03-28
CN108650881A (zh) 2018-10-12
FR3047177B1 (fr) 2020-02-07
FR3047175A1 (fr) 2017-08-04

Similar Documents

Publication Publication Date Title
WO2017129779A1 (fr) Compositions cosmetiques, dermatologiques comprenant un extrait de vitex negundo enrichi en polyphenols
JP5970148B2 (ja) チロシナーゼ活性阻害剤、メラニン産生抑制剤、及びＳＣＦｍＲＮＡ発現抑制剤
EP1845935B1 (de) Verwendung von silymarin und/oder den bestandteilen davon als promotoren der pigmentierung von haut oder haaren
EP3060228B1 (de) Fettextrakt aus maracujasamen
EP2654762B1 (de) Extrakte aus den oberirdische teile des gynandropsis gynandra und kosmetische, dermatologische sowie pharmazeutische zusammensetzungen die diese extrakte beinhalten
EP3727603B1 (de) Kapokbaumblütenextrakt und kosmetische, pharmazeutische oder dermatologische zusammensetzungen damit
EP3113850B1 (de) Hautaufhellende kosmetikzusammensetzung
FR3106754A1 (fr) Procede d’obtention d’un extrait aqueux de lavande, compositions comprenant un tel extrait et leurs utilisations cosmetiques
EP2276457B1 (de) Verwendung von myrtenextrakt als depigmentierungsmittel
WO2012172199A1 (fr) Composition a base de camellia japonica et polygonum hydropiper pour protection de la peau
FR2779645A1 (fr) Compositions a usage cosmetique ou dermopharmaceutique contenant un melange d'extrait de cafe vert et de beurre de karite
EP1768684B1 (de) Zusammensetzung enthaltend extrakte von blauem lotus zur behandlung von unkontrollierten gesichtsmuskelkontraktionen
FR3051369B1 (fr) Extraits de faine de hetre, compositions et utilisations
WO2018172379A1 (fr) Utilisation d'un extrait de copaifera contre l'alopecie et la seborrhee
EP3042662A1 (de) Salatextrakte, zusammensetzungen und anwendungen
FR3110345A1 (fr) Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques.
EP3787592B1 (de) Kombination von extrakten von chinarinde und leontopodium alpinum und des mangansalzes von l-pyrrolidoncarbonsäure zur behandlung von alopezie
EP1566168A1 (de) Hautkosmetische Zubereitungen zur Depigmentierung und deren Verwendung
FR2871382A1 (fr) Composition comprenant un complexe d'extraits vegetaux, a effet decontractant de la peau
FR3107834A1 (fr) Utilisation d’une association d’huiles essentielles pour ameliorer la surface de la peau
FR3076734A1 (fr) Nouvelle utilisation cosmetique d'un extrait de nephelium lappaceum
FR3065877A1 (fr) Extraits d’aiguilles de sapin, compositions et utilisations
FR2871380A1 (fr) Composition comprenant un extrait vegetal a effet decontractant de la peau
FR2871381A1 (fr) Composition comprenant un extrait vegetal a effet decontractant de la peau
FR2975599A1 (fr) Utilisation d'un vegetal du genre lannea dans la preparation d'une composition a effet vaso-constricteur

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180829

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/216 20060101ALI20201202BHEP

Ipc: A61Q 17/00 20060101ALI20201202BHEP

Ipc: A61K 9/06 20060101ALI20201202BHEP

Ipc: A61K 45/06 20060101ALI20201202BHEP

Ipc: A61K 9/00 20060101ALI20201202BHEP

Ipc: A61Q 19/08 20060101ALI20201202BHEP

Ipc: A61K 36/85 20060101ALI20201202BHEP

Ipc: A61K 8/9789 20170101ALI20201202BHEP

Ipc: A61P 17/10 20060101ALI20201202BHEP

Ipc: A61P 43/00 20060101ALI20201202BHEP

Ipc: A61Q 19/02 20060101ALI20201202BHEP

Ipc: A61P 17/18 20060101ALI20201202BHEP

Ipc: A61K 47/14 20170101ALI20201202BHEP

Ipc: A61P 17/04 20060101ALI20201202BHEP

Ipc: A61K 8/34 20060101AFI20201202BHEP

Ipc: A61P 9/00 20060101ALI20201202BHEP

Ipc: A61P 17/00 20060101ALI20201202BHEP

Ipc: A61Q 5/00 20060101ALI20201202BHEP

Ipc: A61K 47/10 20170101ALI20201202BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210601